In an interim analysis, researchers reported on the open-label extension period on safety and tolerability of VidoCa in relapsing-remitting MS.
Researchers sought to report MRI, efficacy, and safety outcomes at week 96 of the phase 2b trial long-term safety extension in patients with relapsing MS and highly active disease.
Researchers sought to assess the relationship between obesity and diagnosis of myelin oligodendrocyte glycoprotein–associated disease and neuromyelitis optica in a diverse population.
Using optical coherence tomography angiography, researchers compared retinal microvasculature in patients with MS vs healthy individuals.
Researchers sought to describe the risk and outcomes for COVID-19 infection in patients with NMOSD who receive inebilizumab.
Researchers sought to examine the effects of fatigue on cognition in patients with MS via the MFIS and SDMT, before and during MEG study.
Researchers sought to compare real-world safety profiles of dimethyl fumarate and fingolimod via data from the FDA’s Adverse Event Reporting System database.
Researchers sought to compare the effects of a diet and therapeutic lifestyle telehealth intervention vs standard of care on perceived quality of life and fatigue in patients newly diagnosed with CIS or RRMS.
In a secondary data analysis, researchers estimated health resource utilization (HRU), including infection-related HRU, relapses, and costs in patients with stable MS who switched from anti-CD20 to fumarate.
Researchers reported on the primary safety and efficacy data from patients with early RRMS, treated with ocrelizumab over 4 years in the open-label, single-arm, phase 3b ENSEMBLE study.
Researchers sought to investigate the humoral response of patients with RMS, treated with evobrutinib who received mRNA and non-mRNA COVID-19 vaccines during the open-label extension of a phase II clinical trial.
In a retrospective, cross-sectional study, researchers characterized MS presentation in Latinx patients compared with non-White Latinx patients.
Researchers sought to examine neurologic care spatial access disparities among various demographics of the US population.
Researchers assessed the impact of seizures in patients with dementia on clinical and mortality outcomes.
Researchers aimed to evaluate the clinical efficacy of virtual reality as a behavioral modification tool for teaching and supporting the social and communication needs of children with autism.
In a retrospective, cross-sectional study, researchers assessed whether structural changes in the amygdala occur during the earliest stages of Alzheimer disease.
In a case-control study, researchers assessed whether objective gait abnormality would be a cost-effective screening tool for posterior circulation stroke.
Researchers sought to identify associations of traumatic brain injury history and subsequent diagnosis of multiple sclerosis among post-9/11 era veterans.
Researchers sought to assess the efficacy, safety, and tolerability of ubrogepant 100 mg when administered during the prodrome of a migraine attack.
Researchers aimed to identify the national geographic patterns of Parkinson disease and test for nationwide and region-specific associations with PM2.5.
Researchers sought to estimate the associations between traumatic brain injury, mild cognitive impairment, all-cause dementia, and Alzheimer disease dementia.
Researchers sought to determine the role of antibodies and innate immune responses in the pathogenesis of neurologic post-acute sequelae of SARS-CoV-2.
In a retrospective study, researchers investigated disparities along racial/ethnic lines related to the use of medications for managing dementia in an outpatient setting.
Researchers sought to assess the effect of assisted reproductive technologies on relapse risk among women with multiple sclerosis receiving treatment with disease-modifying immunomodulatory treatment.
Study authors evaluated whether donanemab was superior to aducanumab on the percentage of participants with amyloid plaque clearance after 6 months of therapy in patients with early symptomatic AD.
Study authors conducted a global, open-label, phase 3 study to report the safety and efficacy of ravulizumab in patients with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder (AQP4+ NMOSD).
Researchers sought to assess the impact of cognitive symptoms on risk for mortality from COVID-19 in people with HIV.
In a clinical trial, researchers evaluated the efficacy and safety of remote electrical neuromodulation used every other day for migraine prevention.
Researchers sought to assess the long-term effect of ofatumumab (OMB) on sNfL levels and NEDA-3 in patients with relapsing MS who receive continuous OMB and those who converted from teriflunomide in ASCLEPIOS I/II and ALITHIOS.
Researchers described the efficacy and safety results from the placebo-controlled phase of Study 041 on ataluren and change in ambulatory function in patients with Duchenne muscular dystrophy.